Pericytes in the tumor microenvironment.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 21 10 2022
revised: 10 01 2023
accepted: 19 01 2023
pubmed: 23 1 2023
medline: 15 2 2023
entrez: 22 1 2023
Statut: ppublish

Résumé

Pericytes are a type of mural cell located between the endothelial cells of capillaries and the basement membrane, which function to regulate the capillary vasomotor and maintain normal microcirculation of local tissues and organs and have been identified as a significant component in the tumor microenvironment (TME). Pericytes have various interactions with different components of the TME, such as constituting the pre-metastatic niche, promoting the growth of cancer cells and drug resistance through paracrine activity, and inducing M2 macrophage polarization. While changes in the TME can affect the number, phenotype, and molecular markers of pericytes. For example, pericyte detachment from endothelial cells in the TME facilitates tumor cells in situ to invade the circulating blood and is beneficial to local capillary basement membrane enzymatic hydrolysis and endothelial cell proliferation and budding, which contribute to tumor angiogenesis and metastasis. In this review, we discuss the emerging role of pericytes in the TME, and tumor treatment related to pericytes. This review aimed to provide a more comprehensive understanding of the function of pericytes and the relationship between pericytes and tumors and to provide ideas for the treatment and prevention of malignant tumors.

Identifiants

pubmed: 36682706
pii: S0304-3835(23)00025-3
doi: 10.1016/j.canlet.2023.216074
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

216074

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Zhongyi Jiang (Z)

NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan, 410078, China.

Jing Zhou (J)

NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan, 410078, China.

Luohong Li (L)

NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan, 410078, China.

Shan Liao (S)

Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.

Junyu He (J)

NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan, 410078, China.

Shubo Zhou (S)

Department of Neurosurgery, Yiyang Central Hospital, 118 Kang Fu Road, Yiyang, Hunan Province, 413000, China. Electronic address: zhoushubo886@163.com.

Yanhong Zhou (Y)

NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan, 410078, China. Electronic address: zhouyanhong@csu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH